C. L. Vogel

Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.

D. Hayes, C. Vogel, W. Bezwoda, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer.

M. Green, R. Gams, I. Shemano, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monotherapy of metastatic breast cancer: a review of newer agents.

C. Vogel, J. Nabholtz, C. L. Vogel, 1999, The oncologist.

Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.

V. Georgoulias, C. Vogel, L. Alland, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Lyndsay N Harris, L. Harris, S. Shak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.

A Howell, A. Howell, A. Buzdar, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.